



August 3, 2017

Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at Canaccord Genuity 37th Annual Growth Conference in Boston on Thursday, August 10, 2017 at 12:30 p.m. EDT.

A live webcast can be accessed from the Investors & Media section of Eleven's website, www.elevenbio.com. An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information please refer to the Company's website at www.elevenbio.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170803005690/en/>

Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

Source: Eleven Biotherapeutics, Inc.

News Provided by Acquire Media